MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag133

Медицинская библиотека · The oncologist · 2026

Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors.

Sun Haishuang, Chen Gang, Xue Jinhui, Zhang Yaxiong, Ma Yuxiang, Yang Yunpeng, Fang Wenfeng, Zhao Yuanyuan, Huang Yan, Hong Shaodong, Zhou Ting, Zhao Shen, Zhou Huaqiang, Chen Xi, Li Jing, Zhang Li, Zhao Hongyun

СтатьяКлиническое исследование I фазыМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Y101D is a novel bispecific antibody targeting PD-L1 and TGF-β. This multicenter phase I study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of Y101D in patients with metastatic or locally advanced solid tumors.

METHODS

Patients who failed standard therapies were enrolled. In the dose-escalation and -expansion phases, Y101D was administered intravenously every 2 weeks (Q2W) at 1, 3, 10, 20, and 30 mg/kg. Primary objectives were dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) in escalation, safety, and objective response rate (ORR) in expansion. Secondary objectives included pharmacokinetics/pharmacodynamics parameters, and immunogenicity.

RESULTS

Among 50 enrolled patients, the most common treatment-related adverse events (TRAEs) were aspartate aminotransferase elevation (20.0%), gingival bleeding (18.0%), alanine aminotransferase elevation (14.0%), rash (14.0%), and proteinuria (14.0%). Grade ≥ 3 TRAEs occurred in 10.0% of patients, with no grade 4/5 TRAEs. Immune-related adverse events (irAEs) occurred in 22.0%, predominantly grades 1-2. No DLTs were observed, and MTD was not reached. One extensive-stage small cell lung cancer (ES-SCLC) patient (20 mg/kg Q2W) achieved a confirmed partial response (ORR: 2.1%, 95% CI, 0.1%-11.3%). Median progression-free survival and overall survival were 1.3 months (95% CI, 0.9-1.3) and 10.5 months (95% CI, 6.6-12.7), respectively. The pharmacokinetic characteristics of single and multiple doses of 20 mg/kg Q3W and 1200 mg Q3W supported the administration schedule of once every 3 weeks. PD-L1 target occupancy exceeded 95% at 2 h post-dose across all cohorts and remained sustained pre-dose.

CONCLUSIONS

Y101D monotherapy exhibited a manageable safety profile and on-target pharmacodynamic activity, with limited antitumor activity as a single agent. Further evaluation in disease-focused cohorts and rational combination regimens is warranted, including in ES-SCLC.

CLINICAL TRIAL NUMBER REGISTRATION: NCT05028556.

Для цитирования: Sun Haishuang, Chen Gang, Xue Jinhui, Zhang Yaxiong, Ma Yuxiang, Yang Yunpeng, Fang Wenfeng, Zhao Yuanyuan, Huang Yan, Hong Shaodong, Zhou Ting, Zhao Shen, Zhou Huaqiang, Chen Xi, Li Jing, Zhang Li, Zhao Hongyun. Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag133.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.